{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:09:12Z","timestamp":1771070952327,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,14]]},"DOI":"10.7759\/cureus.103585","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:33:11Z","timestamp":1771068791000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Risankizumab in a Patient With Complex Crohn\u2019s Disease and a High-Output Ileostomy: A Case Report"],"prefix":"10.7759","author":[{"given":"Sarah I","family":"Zahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kifaya","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayham Khan","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia I","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad I","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn's disease: a Belgian multicentric cohort study","volume":"30","author":"Alsoud D","year":"2024","unstructured":"Alsoud D, Sabino J, Franchimont D, et al.. Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn's disease: a Belgian multicentric cohort study. Inflamm Bowel Dis. 2024, 30:2289-96. 10.1093\/ibd\/izad315","journal-title":"Inflamm Bowel Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens G","year":"2022","unstructured":"D'Haens G, Panaccione R, Baert F, et al.. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022, 399:2015-30. 10.1016\/S0140-6736(22)00467-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf070","article-title":"A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's disease","volume":"19","author":"Johnson AM","year":"2025","unstructured":"Johnson AM, Askar M, Belani S, et al.. A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's disease. J Crohns Colitis. 2025, 19:070. 10.1093\/ecco-jcc\/jjaf070","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.035","article-title":"AGA clinical practice update on management of ostomies: commentary","volume":"21","author":"Hedrick TL","year":"2023","unstructured":"Hedrick TL, Sherman A, Cohen-Mekelburg S, Gaidos JKJ. AGA clinical practice update on management of ostomies: commentary. Clin Gastroenterol Hepatol. 2023, 21:2473-7. 10.1016\/j.cgh.2023.04.035","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17358","article-title":"Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort study","volume":"57","author":"Fumery M","year":"2023","unstructured":"Fumery M, Defrance A, Roblin X, et al.. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort study. Aliment Pharmacol Ther. 2023, 57:426-34. 10.1111\/apt.17358","journal-title":"Aliment Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"120","author":"Lichtenstein GR","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, et al.. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2025, 120:1225-64. 10.14309\/ajg.0000000000003465","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040447","article-title":"New interleukin-23 antagonists' use in Crohn's disease","volume":"18","author":"Biskup L","year":"2025","unstructured":"Biskup L, Semeradt J, Rogowska J, Chort W, Durko \u0141, Ma\u0142ecka-Wojciesko E. New interleukin-23 antagonists' use in Crohn's disease. Pharmaceuticals (Basel). 2025, 18:447. 10.3390\/ph18040447","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante M","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al.. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022, 399:2031-46. 10.1016\/S0140-6736(22)00466-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17242","article-title":"Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials","volume":"57","author":"Peyrin-Biroulet L","year":"2023","unstructured":"Peyrin-Biroulet L, Ghosh S, Lee SD, et al.. Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Aliment Pharmacol Ther. 2023, 57:496-508. 10.1111\/apt.17242","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy025","article-title":"Management of Crohn's disease and complications in patients with ostomies","volume":"24","author":"Wang X","year":"2018","unstructured":"Wang X, Shen B. Management of Crohn's disease and complications in patients with ostomies. Inflamm Bowel Dis. 2018, 24:1167-84. 10.1093\/ibd\/izy025","journal-title":"Inflamm Bowel Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw200","article-title":"Development of the Harvey-Bradshaw Index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn's disease","volume":"11","author":"Zittan E","year":"2017","unstructured":"Zittan E, Kabakchiev B, Kelly OB, et al.. Development of the Harvey-Bradshaw Index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn's disease. J Crohns Colitis. 2017, 11:543-8. 10.1093\/ecco-jcc\/jjw200","journal-title":"J Crohns Colitis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.11.303","article-title":"AGA clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review","volume":"166","author":"Hashash JG","year":"2024","unstructured":"Hashash JG, Elkins J, Lewis JD, Binion DG. AGA clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review. Gastroenterology. 2024, 166:521-32. 10.1053\/j.gastro.2023.11.303","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.05.032","article-title":"AGA clinical practice update on management of short bowel syndrome: expert review","volume":"20","author":"Iyer K","year":"2022","unstructured":"Iyer K, DiBaise JK, Rubio-Tapia A. AGA clinical practice update on management of short bowel syndrome: expert review. Clin Gastroenterol Hepatol. 2022, 20:2185-94. 10.1016\/j.cgh.2022.05.032","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14136","article-title":"Systematic review: pharmacotherapy for high-output enterostomies or enteral fistulas","volume":"46","author":"de Vries FE","year":"2017","unstructured":"de Vries FE, Reeskamp LF, van Ruler O, et al.. Systematic review: pharmacotherapy for high-output enterostomies or enteral fistulas. Aliment Pharmacol Ther. 2017, 46:266-73. 10.1111\/apt.14136","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/436841-efficacy-and-safety-of-risankizumab-in-a-patient-with-complex-crohns-disease-and-a-high-output-ileostomy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:33:12Z","timestamp":1771068792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/436841-efficacy-and-safety-of-risankizumab-in-a-patient-with-complex-crohns-disease-and-a-high-output-ileostomy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.103585","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}